Assessing Ovarian Reserve
Female cancer survivors are at risk for decreased fertility and early menopause usually due to the impact of therapy on oocytes and ovaries. The ability to assess ovarian reserve or the number of oocytes in the ovaries may significantly improve care by elucidating which therapies and patients are at a higher risk of ovarian failure, as well as which patients would benefit most from fertility preservation therapies. Current markers of ovarian reserve were developed and have been well studied in infertile populations; thus, their utility in children and adolescents who undergo cancer therapy remains unknown. This chapter will discuss currently used markers of fertility and ovarian reserve and their implications in girls with cancer.
KeywordsOvarian reserve Premature ovarian insufficiency Infertility Antral follicle count Anti-Mullerian hormone
- 23.Gupta AA, Lee Chong A, Deveault C, Traubici J, Maloney AM, Knight S, Lorenzo A, Allen L. Anti-Müllerian hormone in female adolescent cancer patients before, during, and after completion of therapy: a pilot feasibility study. J Pediatr Adolesc Gynecol. 2016;29(6):599–603.CrossRefPubMedCentralGoogle Scholar
- 24.van der Kooi AL, van den Heuvel-Eibrink MM, van Noortwijk A, Neggers SJ, Pluijm SM, van Dulmen-den Broeder E, van Dorp W, Laven JS. Longitudinal follow-up in female childhood cancer survivors: no signs of accelerated ovarian function loss. Hum Reprod. 2017;32(1):193–200.PubMedPubMedCentralGoogle Scholar